SYK Q2 Deep Dive: Tariffs, Supply Chain, and Robotics Weigh on Market Sentiment

Medical technology company Stryker (NYSE:SYK) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 11.1% year on year to $6.02 billion. Its non-GAAP profit of $3.13 per share was 1.9% above analysts’ consensus estimates.

Is now the time to buy SYK? Find out in our full research report (it’s free).

StockStory’s Take

Stryker’s second quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and profit expectations. Management described robust demand across its core product portfolio, particularly highlighting double-digit growth in MedSurg and Neurotechnology and solid performance in orthopedics. CEO Kevin Lobo pointed to strong U.S. momentum, driven by procedural volume growth, expanding adoption of robotic-assisted surgery, and healthy hospital capital spending. However, lingering supply chain challenges in the Medical division and ongoing tariff impacts tempered the overall narrative.

Looking forward, Stryker’s updated guidance is informed by sustained strength in procedural volumes, continued product launches, and operational improvements. CFO Preston Wells emphasized disciplined cost management and manufacturing efficiency as key levers to offset tariff headwinds. Management remains focused on the ongoing integration of recent acquisitions and the rollout of new robotic applications, with Lobo stating, “We are confident in the durability of our growth and earnings power across our businesses.” While supply issues in the Medical division persist, leadership expects acceleration in growth as new products receive regulatory clearance and enter international markets.

Key Insights from Management’s Remarks

Stryker’s management attributed the quarter’s revenue outperformance to robust procedural demand, expanding robotic installations, and continued product innovation, while acknowledging lingering supply and tariff pressures.

• Robotic-assisted surgery adoption: The company experienced record installations and utilization of its Mako robotic systems, with expanded applications such as revision hip and spine driving growth in orthopedics. Management noted international adoption is still in early stages, presenting further runway.

• Endoscopy and sports medicine momentum: Double-digit growth in endoscopy was fueled by hospital infrastructure demand and the successful 1788 video platform, as well as new shoulder product launches in sports medicine. These product launches helped the division outperform prior trends.

• Supply chain bottlenecks: Persistent supply disruptions in the Medical division impacted emergency care product availability, though LIFEPAK 35 and acute care lines continued to perform strongly. Management expects these issues to last through year-end but sees them as contained.

• Tariff headwinds: Tariff expenses remained a drag, though the estimated annual impact moderated from $200 million to $175 million due to changes in U.S.-China and European tariff frameworks. Stryker is leveraging manufacturing efficiency and pricing initiatives to help offset these headwinds.

• Inari integration and leadership changes: The integration of Inari Medical involved replacing key sales and marketing leaders and onboarding new sales professionals. While initial destocking and turnover created noise, management believes the business is now positioned for double-digit growth, citing a strong procedural pipeline and expanding international opportunities.

Drivers of Future Performance

Stryker’s outlook is shaped by the resilience of procedural demand, new product launches, and margin management amid ongoing external headwinds.

• Sustained procedural strength: Management expects continued healthy volumes in elective and trauma procedures, supported by demographic trends and increased adoption of robotic-assisted surgery. This trend, particularly in ambulatory surgery centers, is viewed as a long-term driver for orthopedics and MedSurg growth.

• Margin discipline amid tariffs: Stryker’s focus on manufacturing efficiency, pricing, and operating expense control is expected to help offset remaining tariff impacts and supply chain costs. Wells highlighted ongoing lean initiatives and procurement optimization as supporting margin stability.

• International product rollout: The company anticipates accelerated growth in international markets as key products like LIFEPAK 35, Insignia, and Pangea move through regulatory approval and launch. Delays in the European regulatory environment have pushed some launches into next year, but leadership sees eventual global expansion as a major growth lever.

Catalysts in Upcoming Quarters

As we look to coming quarters, the StockStory team will closely monitor (1) the pace of regulatory approvals and international launches for key products like LIFEPAK 35 and Insignia, (2) the resolution of supply chain issues in the Medical division and their effect on volume recovery, and (3) the continued momentum in robotic installations and procedural adoption. Additionally, we will watch how Stryker’s operating discipline manages ongoing tariff and cost headwinds.

Stryker currently trades at $376.01, down from $394.22 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.